<DOC>
	<DOCNO>NCT00259376</DOCNO>
	<brief_summary>To assess efficacy dronedarone versus placebo maintenance normal sinus rhythm electrical , pharmacological spontaneous conversion atrial fibrillation/atrial flutter ( AF/AFL ) . To assess efficacy dronedarone versus placebo ventricular rate control case AF/AFL recurrence . To assess efficacy dronedarone versus placebo AF/AFL-related symptom .</brief_summary>
	<brief_title>American-Australian-African Trial With Dronedarone Patients With Atrial Fibrillation Atrial Flutter Maintenance Sinus Rhythm</brief_title>
	<detailed_description>This double-blind , parallel arm , placebo-controlled , multicentre , multinational , phase III study . To eligible , patient must normal sinus rhythm randomisation must ECG-documented history recent AF/AFL revert normal sinus rhythm electrical , pharmacological spontaneous conversion .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Patients either sex age 21 year , sinus rhythm least 1 hour time randomisation least one ECGdocumented AF/AFL episode last 3 month . MAIN CRITERIA ( nonexhaustive list , see protocol detail ) : Women childbearing potential without adequate birth control , Pregnant woman , Breastfeeding woman , Congestive heart failure NYHA class III IV , Conditions increase risk severe antiarrhythmic drug side effect , Severe associate condition .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Atrial Flutter</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Anti-Arrhythmia agent</keyword>
</DOC>